The global In Vitro Fertilization (IVF) Market was valued at USD 15.72 Billion in 2022 and is projected to reach USD 33 Billion by 2030, growing at a CAGR of 8.6% from 2023 to 2030.

In Vitro Fertilization (IVF) Market Overview:

In vitro fertilization (IVF) is one of the most common types of assisted reproductive technology (ART), and it works by using both medicine and surgery. IVF helps an embryo grow and implant in a couple that can't have children on its own. IVF is the process of making a baby by taking out an egg, getting a sample of sperm, and then putting the egg and sperm together by hand in a lab. The growing use of IVF has led to about half a million babies being born each year using IVF or other methods of assisted reproduction. So, more people are likely to use in vitro fertilization (IVF) treatments during the forecast period as IVF and ICSI become more popular.

But the high cost and risks of IVF and ICSI treatments will keep the IVF market from growing as fast as it could over the next few years. For example, the Reproductive Science Center published data that showed that some IVF procedures were linked to a rare condition called "Imprinting Disorders." The risk of Imprinting Disorders with IVF treatment was estimated to be between 2 and 5 per 15,000 births using the IVF technique, while the risk, in general, was 1 per 15,000 births. So, the possible risks and birth defects that come with IVF treatment can make it harder for people all over the world to use IVF or ICSI.

In Vitro Fertilization (IVF) Market Dynamics

Market Drivers

Growth in median age of first-time mothers

Over time, the average age of first-time mothers has gone up a lot all over the world. This trend is mostly caused by better birth control methods, women getting married later, and more women putting their careers ahead of starting a family. The average age of first-time mothers in Australia rose from 27.9 years in 2009 to 31.9 years in 2019. This is according to data from the Australian Institute of Health and Welfare 2021. As the average age of first-time mothers goes up, more and more women are likely to have trouble getting pregnant on their own. In this situation, more and more women are being forced to choose IVF treatments. This is likely to make the IVF market grow in the coming years.

Restraints

High costs associated with IVF procedures

Every year, more than 2.5 million IVF (in vitro fertilisation) cycles are done around the world. Due to the lack of reimbursement policies, the cost of IVF treatment varies from country to country. This market isn't growing as fast as it could because some places don't have insurance and don't have good ways to pay out claims.

Opportunities

Increasing Medical Tourism in Emerging Nations

Due to a number of factors, the medical tourism business in developing countries is doing very well. Brazil has over 20 medical centres and about 150 centres that treat infertility [Source: Fertility Treatment Abroad]. In the US, a typical IVF cycle costs around USD 12,000, but the same thing can be done for USD 4,000 in Brazil. India is one of the most affordable places in the world for in vitro fertilisation (IVF) and other treatments for infertility. It has more than 500 IVF centres. Healthcare costs up to 90% less in India than in the United States. In the US, a typical IVF cycle costs around USD 12,000, but the same thing can be done for USD 2,000–USD 3,000 in India.

In Vitro Fertilization (IVF) Market Segmentation Analysis

Product Insights

In 2021, the fresh non-donor segment led the market in terms of revenue, making up 49% of the market. This is because the chances of success are high, the birth rate is higher than with frozen embryos, it is easy to implant the embryo, and the results are better with a fresh embryo transfer. More people are using the fresh non-donor cycle, and the number of people who can't have children is going up around the world. Due to its growing popularity, this cycle is likely to remain the most popular over the next few years.

During the forecast period, the frozen non-donor segment is likely to grow the most. This is mostly because of how easy it is to get pregnant and how cheap it is. Both the patients and the endocrinologists find frozen transfer to be much easier. Also, the frozen non-donor cycle puts less stress on the physical and mental health of the women, which is expected to help this segment grow in the coming years.

Based on End Use:

In 2021, fertility clinics made up 80% of the revenue share based on the end user. Fertility clinics are where couples go first when they are having trouble getting pregnant. Fertility clinics are specialized clinics that help couples and single people who are having trouble getting pregnant or having children. The fertility clinics market is growing around the world because there are more of them, more people know about them, and birth rates are going down.

During the time frame of the forecast, hospitals are expected to be the most promising segment. Hospital services are in high demand because there are a lot of them, healthcare is getting better in developing countries, doctors and nurses are there 24 hours a day, seven days a week, and hospitals have advanced tools and equipment for surgery.

Regional Insights:

During the Forecast period, Europe is anticipated to be the largest market by region.

In 2021, more than 38% of all revenue from the in vitro fertilization market came from Europe. This made Europe the market leader. In the coming years, the regional market will grow because of things like the rise of medical tourism and changes in the law about IVF techniques. People from the U.S. are going to the Czech Republic more and more to get IVF treatments at lower prices. According to an ESHRE fact sheet, almost all EU member states offer some kind of reimbursement for ART as of January 2017. (except Lithuania and Ireland). From 2022 to 2030, the IVF market is expected to grow the fastest in Asia-Pacific.

In the Asia-Pacific region, there will be a lot more people wanting IVF treatments because of fertility tourism, more foreign investment in economically developing countries, and changing laws. Infertility has become more common because of changes in lifestyles, such as more people being overweight and stressed, not getting enough exercise, eating badly, not getting enough nutrition, and living in places with more pollution, as well as because of more people having health problems like diabetes. In the coming years, fertility treatments are also likely to become more popular in North America. The IVF market in North America is growing because of things like the automation of procedures, changes to regulations, government funding for egg and sperm storage, and the introduction of more IVF treatments by industry players.

Scope Analysis

Recent Development

• In 2021, Hamilton Thorne Ltd. received FDA approval for commercialization of GYNEMED GM501, a ready-to-use medium designed for in vitro washing and handling procedures of human oocytes and embryos in the United States and Europe.
• In 2021, CooperSurgical announced a partnership with Virtus Health to strengthen infertility technology and increase access to advanced treatments for infertile couples.
• In 2020, FUJIFILM Irvine Scientific announced the release of Vit Kit-NX, a vitrification media solution.
• In 2020, Genea Limited partnered with Hamilton Thorne Ltd. to commercialize Genea limited fertility products in the United States and Canada.
• July 2019: Shady Grove Fertility announced the opening of a new full-service in vitro fertilization (IVF) center in Tampa, Florida.
• May 2019: Scientists at Monash IVF have developed a new embryo screening test to reduce the risk of miscarriage during IVF treatment.

The Global In Vitro Fertilization (IVF) Market has been segmented into:

By Type

• Intrauterine Insemination,
• Intracytoplasmic Sperm Injection,
• IVF Using Donor Eggs

By Devices

• Imaging Systems
• Sperm Separation System
• Ovum Aspiration Pump
• Micromanipulator
• Cryosystem

By Reagents

• Embryo Culture Media,
• Cryopreservation Media
• Sperm Processing Media
• Ovum Processing Media

By End-User

• Fertility Clinics
• Hospitals
• Clinical Research Centers

By Companies

• Cooper Companies Inc. (US)
• Cook Group (US)
• Vitrolife (Sweden)
• Thermo Fisher ScientificInc. (US)
• Esco Micro Pte. Ltd. (Singapore)
• Genea Limited (Australia)
• IVFtech ApS (Denmark)
• FUJIFILM Irvine Scientific (US)
• The Baker CompanyInc. (US)
• Kitazato Corporation (Japan)
• Rocket Medical plc (UK)
• Hamilton Thorne Ltd. (US)
• ZEISS Group (Germany)
• FERTIPRO NV(Belgium)
• Gynotec B.V. (Netherlands)